Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell Carcinoma
A paucity of advances in the development of novel therapeutic agents for squamous cell carcinomas of the head and neck, oral cavity (OSCC) and oropharynx, has stagnated disease free survival rates over the past two decades. Although immunotherapies targeted against checkpoint inhibitors such as PD-1...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-05-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/8/5/611 |
id |
doaj-9ad4636ad4144d908e5a7bc6604dc6f9 |
---|---|
record_format |
Article |
spelling |
doaj-9ad4636ad4144d908e5a7bc6604dc6f92020-11-25T00:39:35ZengMDPI AGJournal of Clinical Medicine2077-03832019-05-018561110.3390/jcm8050611jcm8050611Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell CarcinomaPriyanka Shah O’Brien0Yue Xi1Justin R. Miller2Amy L. Brownell3Qinghua Zeng4George H. Yoo5Danielle M. Garshott6Matthew B. O’Brien7Anthony E. Galinato8Peter Cai9Neha Narula10Michael U. Callaghan11Randal J. Kaufman12Andrew M. Fribley13Department of Otolaryngology–Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI 48201, USACarman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI 48201, USACarman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI 48201, USACarman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI 48201, USADivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USADepartment of Otolaryngology–Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI 48201, USACarman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI 48201, USAHenry Ford Hospital, Diagnostic Radiology Residency, Detroit, MI 48202, USAHenry Ford Hospital, Diagnostic Radiology Residency, Detroit, MI 48202, USAWayne State University School of Medicine, Detroit, MI 48201, USAWayne State University School of Medicine, Detroit, MI 48201, USACarman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI 48201, USADegenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USADepartment of Otolaryngology–Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI 48201, USAA paucity of advances in the development of novel therapeutic agents for squamous cell carcinomas of the head and neck, oral cavity (OSCC) and oropharynx, has stagnated disease free survival rates over the past two decades. Although immunotherapies targeted against checkpoint inhibitors such as PD-1 or CTLA-4 are just now entering the clinic for late stage disease with regularity the median improvement in overall survival is only about three months. There is an urgent unmet clinical need to identify new therapies that can be used alone or in combination with current approaches to increase survival by more than a few months. Activation of the apoptotic arm of the unfolded response (UPR) with small molecules and natural products has recently been demonstrated to be a productive approach in pre-clinical models of OSCC and several other cancers. The aim of current study was to perform a high throughput screen (HTS) with a diverse chemical library to identify compounds that could induce CHOP, a component of the apoptotic arm of the UPR. Disulfiram (DSF, also known as Antabuse) the well-known aversion therapy used to treat chronic alcoholism emerged as a hit that could generate reactive oxygen species, activate the UPR and apoptosis and reduce proliferation in OSCC cell cultures and xenografts. A panel of murine embryonic fibroblasts null for key UPR intermediates (e.g., Chop and Atf4) was resistant to DSF suggesting that an intact UPR is a key element of the mechanism regulating the antiproliferative effects of DSF.https://www.mdpi.com/2077-0383/8/5/611HNSCChead and neck cancerhigh throughput screenHTSAntabusedisulfiramNSC-1771ROSunfolded protein responseER stressOSCCoral cancer |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Priyanka Shah O’Brien Yue Xi Justin R. Miller Amy L. Brownell Qinghua Zeng George H. Yoo Danielle M. Garshott Matthew B. O’Brien Anthony E. Galinato Peter Cai Neha Narula Michael U. Callaghan Randal J. Kaufman Andrew M. Fribley |
spellingShingle |
Priyanka Shah O’Brien Yue Xi Justin R. Miller Amy L. Brownell Qinghua Zeng George H. Yoo Danielle M. Garshott Matthew B. O’Brien Anthony E. Galinato Peter Cai Neha Narula Michael U. Callaghan Randal J. Kaufman Andrew M. Fribley Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell Carcinoma Journal of Clinical Medicine HNSCC head and neck cancer high throughput screen HTS Antabuse disulfiram NSC-1771 ROS unfolded protein response ER stress OSCC oral cancer |
author_facet |
Priyanka Shah O’Brien Yue Xi Justin R. Miller Amy L. Brownell Qinghua Zeng George H. Yoo Danielle M. Garshott Matthew B. O’Brien Anthony E. Galinato Peter Cai Neha Narula Michael U. Callaghan Randal J. Kaufman Andrew M. Fribley |
author_sort |
Priyanka Shah O’Brien |
title |
Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell Carcinoma |
title_short |
Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell Carcinoma |
title_full |
Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell Carcinoma |
title_fullStr |
Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell Carcinoma |
title_full_unstemmed |
Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell Carcinoma |
title_sort |
disulfiram (antabuse) activates ros-dependent er stress and apoptosis in oral cavity squamous cell carcinoma |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2019-05-01 |
description |
A paucity of advances in the development of novel therapeutic agents for squamous cell carcinomas of the head and neck, oral cavity (OSCC) and oropharynx, has stagnated disease free survival rates over the past two decades. Although immunotherapies targeted against checkpoint inhibitors such as PD-1 or CTLA-4 are just now entering the clinic for late stage disease with regularity the median improvement in overall survival is only about three months. There is an urgent unmet clinical need to identify new therapies that can be used alone or in combination with current approaches to increase survival by more than a few months. Activation of the apoptotic arm of the unfolded response (UPR) with small molecules and natural products has recently been demonstrated to be a productive approach in pre-clinical models of OSCC and several other cancers. The aim of current study was to perform a high throughput screen (HTS) with a diverse chemical library to identify compounds that could induce CHOP, a component of the apoptotic arm of the UPR. Disulfiram (DSF, also known as Antabuse) the well-known aversion therapy used to treat chronic alcoholism emerged as a hit that could generate reactive oxygen species, activate the UPR and apoptosis and reduce proliferation in OSCC cell cultures and xenografts. A panel of murine embryonic fibroblasts null for key UPR intermediates (e.g., Chop and Atf4) was resistant to DSF suggesting that an intact UPR is a key element of the mechanism regulating the antiproliferative effects of DSF. |
topic |
HNSCC head and neck cancer high throughput screen HTS Antabuse disulfiram NSC-1771 ROS unfolded protein response ER stress OSCC oral cancer |
url |
https://www.mdpi.com/2077-0383/8/5/611 |
work_keys_str_mv |
AT priyankashahobrien disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma AT yuexi disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma AT justinrmiller disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma AT amylbrownell disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma AT qinghuazeng disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma AT georgehyoo disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma AT daniellemgarshott disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma AT matthewbobrien disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma AT anthonyegalinato disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma AT petercai disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma AT nehanarula disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma AT michaelucallaghan disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma AT randaljkaufman disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma AT andrewmfribley disulfiramantabuseactivatesrosdependenterstressandapoptosisinoralcavitysquamouscellcarcinoma |
_version_ |
1725293548232769536 |